- Conditions
- Depressive Disorder, Major
- Interventions
- JNJ-89495120, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 701
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- ExPEC9V, Placebo
- Biological · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 17,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 142
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more
- Conditions
- Asthma, Pulmonary Disease, Chronic Obstructive
- Interventions
- Medical tests
- Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 6 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Simeprevir, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
- Conditions
- Adenocarcinoma of Lung
- Interventions
- JNJ-64041757, Nivolumab
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Nashville, Tennessee • Spokane, Washington
- Conditions
- Healthy
- Interventions
- Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Obesity
- Interventions
- JNJ-64565111
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Waldenström's Macroglobulinemia
- Interventions
- Ibrutinib, Placebo, Rituximab
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 81
- States / cities
- Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- JNJ-38518168, Placebo, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- Healthy
- Interventions
- JNJ-54452840, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 20 Years to 55 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy
- Interventions
- JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- JNJ-809, Apalutamide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more
- Conditions
- Hepatitis B
- Interventions
- JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Depressive Disorder, Major, Anhedonia
- Interventions
- Aticaprant, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Disease
- Interventions
- 111In-DOTA-h11B6
- Drug
- Lead sponsor
- SpectronRX
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 150
- States / cities
- Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
- Conditions
- Metastatic ER+ Her2- Breast Cancer, Postmenopausal
- Interventions
- Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 24
- States / cities
- Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- PIPE-307 Dose A, PIPE-307 Dose B, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Berkeley, California • Colorado Springs, Colorado + 15 more